



Ready-to-use glucagon options available in multiple dosage forms and strengths¹

For the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 2 years and above



Name

GVOKE HypoPen 2-Pack™

Strength

0.5 mg/0.1 mL (Pediatric)

1 mg/0.2 mL (Adult)


NDC

72065-0120-12

72065-0121-12

Administration

Autoinjector



Name

GVOKE PFS 2-Pack™

Strength

1 mg/0.2 mL (Adult)

NDC

72065-0131-12

Administration

Pre-Filled Syringe



Name

GVOKE® Kit

Strength

1 mg/0.2 mL with markings for 0.1 mL (0.5 mg Pediatric) and 0.2 mL (1 mg Adult)

NDC

72065-0140-11

Administration

Vial and Syringe

The Endocrine Society recommends ready-to-use glucagon for all patients with diabetes taking insulin or insulin secretagogues.²

Ensure patients taking insulin or insulin secretagogues have a safety net with GVOKE®



EXPLORE
PATIENT EDUCATION
MATERIALS

Important Safety Information

- GVOKE is contraindicated in patients with:
 - Pheochromocytoma because of the risk of substantial increase in blood pressure

Please see additional Important Safety Information on next page and [full Prescribing Information](#) for GVOKE®.

How to write a prescription for GVOKE®



Product

GVOKE HypoPen 2-Pack™
GVOKE PFS 2-Pack™
GVOKE® Kit



Dosage

0.5 mg/0.1 mL: For patients ages 2-11 and weigh < 100 lbs
1 mg/0.2 mL: For patients ages 12 and up, or weigh ≥ 100 lbs



Dispense: 1 count

For GVOKE HypoPen 2-Pack™ and GVOKE PFS 2-Pack™:

Dose	Quantity
0.5 mg per 0.1 mL	0.2 mL
1 mg per 0.2 mL	0.4 mL



Dispense as written

Write DAW: #1/No substitution



INDICATION

GVOKE (glucagon) is an antihypoglycemic agent indicated for subcutaneous use for the treatment of severe hypoglycemia in adult and pediatric patients aged 2 years and older with diabetes.

IMPORTANT SAFETY INFORMATION

- GVOKE is contraindicated in patients with:
 - Pheochromocytoma because of the risk of substantial increase in blood pressure
 - Insulinoma because of the risk of hypoglycemia
 - Prior hypersensitivity reaction to glucagon or to any of the excipients. Serious hypersensitivity reactions have been reported with glucagon, including generalized rash, and anaphylactic shock with breathing difficulties and hypotension
- GVOKE may stimulate the release of catecholamines from the tumor. If patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate intravenously has been shown to be effective in lowering blood pressure
- In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, administration may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. If a patient develops symptoms of hypoglycemia after a dose of GVOKE, give glucose orally or intravenously
- Patients with insufficient hepatic stores of glycogen may not respond to GVOKE for treatment of severe hypoglycemia. Insufficient hepatic stores of glycogen may be present in conditions such as states of starvation, or in patients with adrenal insufficiency or chronic hypoglycemia
- A skin rash called necrolytic migratory erythema (NME), has been reported post-marketing following continuous glucagon infusion and resolved with discontinuation of the glucagon. GVOKE is not approved for continuous infusion. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks
- Most common adverse reactions reported in adult patients were nausea, vomiting, injection site edema raised 1 mm or greater, and headache
- Most common adverse reactions reported in pediatric patients were nausea, hypoglycemia, vomiting, headache, abdominal pain, hyperglycemia, injection site discomfort and reaction, and urticaria
- Patients taking concomitant beta-blockers may have a transient increase in pulse and blood pressure. In patients taking concomitant indomethacin, GVOKE may lose its ability to raise glucose or may produce hypoglycemia. GVOKE may increase the anticoagulant effect of warfarin

Please see [full Prescribing Information](#) for GVOKE® (glucagon) injection.

* Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, TRICARE, or other federal or state health programs (such as medical assistance programs).

REFERENCES: 1. GVOKE [prescribing information]. Chicago, IL: Xeris Pharmaceuticals, Inc. 2. McCall AL, Lieb DC, Gianchandani R, et al. Management of individuals with diabetes at high risk for hypoglycemia: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2023;108(3):529-562. doi:10.1210/clinem/dgac596

GVOKE®, GVOKE HypoPen®, GVOKE HypoPen 2-Pack™, GVOKE PFS 2-Pack™, Xeris Pharmaceuticals®, and their associated logos are trademarks of Xeris Pharmaceuticals, Inc. Copyright ©2025 Xeris Pharmaceuticals, Inc. All rights reserved. US-GVK-24-00002(v4) 12/25

